Zejula®

Active substance

niraparib

Holder

GlaxoSmithKline Pharmaceuticals S.A./N.V.

Status

Closed

Indication

maintenance treatment of adult female patients with BRCA1/2 wild-type advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer in response following first-line platinumbased chemotherapy

Public documents

Approbation

Approbation amendment

Information for the patient

Informed consent

Last update

10/08/2022

Last updated on 13/02/2024